Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Apr 26, 2024; 16(4): 177-180
Published online Apr 26, 2024. doi: 10.4330/wjc.v16.i4.177
Transcatheter aortic valve replacement in low-risk young population: A double edge sword?
Sukhdeep Bhogal, Akash Batta
Sukhdeep Bhogal, Department of Cardiology, Sovah Health, Martinsville, VA 24112, United States
Akash Batta, Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana 141001, India
Author contributions: Bhogal S and Batta A wrote the manuscript, read and approved the final manuscript; they have contributed equally to this manuscript.
Conflict-of-interest statement: The authors declare no conflict-of-interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Akash Batta, Doctor, MD, Assistant Professor, Researcher, Department of Cardiology, Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana 141001, India. akashbatta02@gmail.com
Received: December 1, 2023
Peer-review started: December 1, 2023
First decision: February 5, 2024
Revised: February 12, 2024
Accepted: March 26, 2024
Article in press: March 26, 2024
Published online: April 26, 2024
Processing time: 143 Days and 15.5 Hours
Core Tip

Core Tip: In 2019, the United States Food and Drug Administration approved transcatheter aortic valve replacement (TAVR) in low-risk patients based on the two large randomized trials. However, patients with certain unfavorable anatomies and clinical profiles were excluded from these trials. Despite the lack of clear evidence in young patients (< 65 years), it may be preferred by this population given the benefits of early discharge, shorter hospital stay, and expedite recovery. Nonetheless, it is important to ruminate various factors including lifetime expectancy, risk of pacemaker implantation, and the need for future valve or coronary interventions in young cohorts before considering TAVR in these patients.